News | July 02, 2022
Ardelyx gets into $20 million financing agreement with HealthCare Royalty Partners
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
Silo enters into commercial evaluation license agreement for next generation liposomes
Brings 25 years of global operations and supply chain experience to Piramal
Bringing next-gen cannabinoid therapeutics to cancer patients
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
Subscribe To Our Newsletter & Stay Updated
